- Shipment made to an established pharmaceutical distributor and clinical research organization in the Czech Republic, focused on medicinal grade cannabinoids
TORONTO and RIONEGRO, Colombia, Sept. 15, 2022 /CNW/ – PharmaCielo Ltd. (“PharmaCielo” or the “Company”) (TSXV: PCLO) (OTCQX: PCLOF), the Canadian parent of Colombia’s premier cultivator and producer of dried cannabis flower and medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S. (“Holdings”), today announced that it has made its first shipment of THC-dominant dried cannabis flower to a customer in the Czech Republic, in the EU market. The customer is an established cannabinoid-focused pharmaceutical distributor and clinical research organization in the country. The customer currently imports cannabinoids from The Netherlands and Canada.
Bill Petron, CEO of PharmaCielo, commented, “PharmaCielo’s global business development team continues to make substantial progress growing the Company’s sales pipeline and setting the stage for accelerated growth beginning in 2023. The EU is the biggest opportunity for global cannabinoid exporters, and PharmaCielo is positioned to win market share against current suppliers, with a combination of proprietary Colombian strains, high quality products and low production costs. Our team has made substantial progress in several markets recently, including Germany, Israel, Brazil, Mexico, Poland, and now the Czech Republic. We expect the combination of these recent developments and sustained sales efforts to make the next eighteen months a pivotal period for the Company.”